GNFT
Genfit S.A.NASDAQHealthcareAs of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
8.19
P/S
9.54
EV/EBITDA
-19.86
DCF Value
$-58.51
FCF Yield
-1.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.1%
Operating Margin
-61.8%
Net Margin
-85.9%
ROE
-63.7%
ROA
-17.9%
ROIC
-13.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $35.5M | $-10.0M | $-0.20 |
| Q4 2024 | $5.9M | $-28.8M | $-0.58 |
| FY 2024 | $67.0M | $1.5M | $0.03 |
| Q2 2024 | $61.1M | $30.3M | $0.50 |
Analyst Ratings
View AllCompany Info
Sector
Healthcare
Industry
—
Country
FR
Exchange
NASDAQ
Beta
0.87
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.